The global cell expansion market is expected to be encouraged by a massive growth on account of a rising demand for regenerative medicines that offer quicker outcomes and cell-based therapies with high patient compatibility. A recent small phase I study discovered the capability of bb2121 to induce a 100.0% objective response rate (ORR) in nine evaluable patients with multiple myeloma. At a 5.0 x 107 chimeric antigen receptor (CAR)-positive T cells or higher dose, the patients were found negative for minimal residual disease (MRD). A 75.0% of them exhibited a very good partial response (VGPR) whereas a complete response (CR) was achieved by a 27.0%. A consistent demonstration of CAR-positive T-cell expansion was observed in all patients.

According to the market intelligence of Transparency Market Research (TMR), the global cell expansion market is anticipated to log a CAGR of 14.7% for the forecast period 2016–2024. By the concluding forecast year, the revenue valuation could touch a US$26.0 bn from a US$7.7 bn recorded in 2015.

Industry players are prognosticated to withstand challenges in the world cell expansion market on the back of the growing prominence of human stem cells. This could be accounted by the growing prevalence of a gamut of chronic diseases and a substantial support from the government. In 2016, the cell type had secured a whopping 58.1% share in the market in respect of revenue. However, players could also find opportunities birthing from other cell type markets such as animal cells that are prophesied to expand at a 14.6% CAGR during the aforesaid forecast period. Animal cells could rise in the market with an impressive growth while riding on the manufacture of vaccines for viral and parasitic diseases.

How will North America Top Global Market?

Having held a 39.3% share in the international cell expansion market in 2016, North America could well be a leading region with a host of business opportunities in the offing. A significant number of key players roofed in the region and augmenting expenditure on research and development are predicted to set the tone for a staggering growth in North America. Although the region could slim down its share by 2024, it is still envisaged to lead the market.

With an exceptional CAGR of 16.4% for the said forecast period, Asia Pacific is foretold to outshine all other regions in the international cell expansion market on the basis of growth rate. The regional market could gain expansively with the mounting trend of outsourcing research procedures to low-cost destinations. Countries such as China, India, Australia, and Japan are envisioned to stoke an increasing growth in the region.